Engflag

Glipizid

Quick links to important sections

Glipizid

Glipizid_IT

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glipizid

Quick Facts

Property Description
Active Ingredient Glipizide
Form Oral tablet (Immediate-release & Extended-release)
Pharmacological Class Antidiabetic agent (Sulfonylurea)
Common Purpose Management of high blood sugar (hyperglycemia)
Origin Synthetic compound

What Type of Medicine is Glipizide and What is Its Purpose?

Glipizide is a synthetic compound classified as an antidiabetic agent, specifically belonging to the second-generation sulfonylurea pharmacological class. As a prescription medication, it is utilized for the systemic management of hyperglycemia and the associated metabolic imbalances of Type 2 Diabetes Mellitus. Glipizide is part of a class of medications known as sulfonylureas that stimulate the release of insulin, which helps to lower elevated blood glucose levels. This mechanism allows Glipizide to act as an effective antihyperglycemic agent to control glucose in the bloodstream. Glipizide's function, which involves directly increasing the body's insulin release, is recognized for providing glucose reduction in patients whose beta-cell function is not completely depleted, which is a typical scenario in early-stage Type 2 Diabetes management.

Glipizide Composition and Form: Active Ingredient and Dosage Type

The medication’s fundamental identity rests upon its single active ingredient, which is the chemical substance known as Glipizide. This compound is synthesized as a derivative of a urea structure, confirming its origin as a synthetic compound. Glipizide is formulated as an oral tablet for oral administration, a convenient dosage form for regular use. It is available in both immediate-release and an extended-release tablet (often referred to as the GITS system) forms. This structural difference is a key differentiator, as the extended-release version is specifically designed to provide a sustained, gradual release of the active ingredient over an extended period, offering continuous glucose control throughout the day.

Regulatory References

  1. NIH StatPearls: Glipizide

What side effects are possible with Glipizid?

Possible Side Effects and Safety Information

The safety profile of Glipizide, a sulfonylurea antidiabetic agent, is formally established by government regulatory bodies. The risk profile is categorized by frequency and the physiological systems affected.

Frequency-Classified Adverse Reactions

The most frequent adverse reaction is hypoglycemia (low blood sugar), which is classified as Very Common and directly reflects the medication's intended action to lower blood glucose. This effect is more likely to occur at the beginning of treatment or during periods of dose adjustment.

Common adverse reactions (occurring in 1% to 10% of patients) often affect the gastrointestinal system (including nausea, diarrhea, and constipation) and the nervous system (dizziness and tremor).

Rare adverse reactions (occurring in less than 0.1% of patients) involve serious effects on the blood and lymphatic system (such as leukopenia, agranulocytosis, and hemolytic anemia) and the hepatobiliary system (cholestatic jaundice).

Serious Adverse Reactions and Safety Considerations

Severe hypoglycemia is the most critical documented serious adverse reaction, potentially leading to seizures or coma.

Safety notes explicitly address specific populations: Older adults are more susceptible to prolonged and difficult-to-recognize hypoglycemia. Individuals with severe renal impairment or severe hepatic impairment face a significantly increased risk of severe hypoglycemia and are subject to regulatory restrictions. The medication is contraindicated in patients with Type 1 diabetes and diabetic ketoacidosis.

Overdose and Emergency Response

The Glipizide overdose profile, as defined by regulatory authorities, centers on the risk of severe or prolonged hypoglycemia (low blood sugar), which is the primary documented metabolic event. Uncorrected, severe hypoglycemia is classified as a medical emergency that can lead to life-threatening outcomes. Officially documented severe manifestations include critical neurological impairment such as seizures, coma, and the potential for permanent impairment of brain function or death. The official guidance states that immediate medical attention is required for any suspected overdose or manifestation of severe hypoglycemia.

For severe reactions, the regulatory guidance mandates immediate hospitalization. Treatment procedures documented in regulatory sources specify the need for a rapid intravenous injection of concentrated (50%) glucose solution. Since no specific antidote is known, management is symptomatic and supportive, focused on maintaining blood glucose levels above 100 mg/dL through continuous infusion.

Following initial stabilization, patients must be closely monitored for a minimum of 24 to 48 hours. This mandatory observation period is necessary because hypoglycemia may recur after apparent clinical recovery. Regulatory notes further indicate that patients with impaired renal or hepatic function and the elderly are susceptible to prolonged hypoglycemia during an overdose event.

Therapeutic Uses of Glipizid

Quick Facts: Glipizid Use

  • Primary Use: Used to help improve blood sugar control.
  • Condition: Indicated for adults with type 2 diabetes mellitus.
  • Application: Utilized alongside physician-recommended diet and exercise programs.

Glipizid is an oral medication approved for use in the management of type 2 diabetes mellitus in adult patients. The primary benefit of Glipizid is its use to help improve and maintain glycemic control, which involves supporting the body to better regulate blood sugar levels. This medication is administered as an addition to lifestyle measures, including diet adjustments and regular physical activity, as part of a complete management plan.

Appropriate blood sugar management may help to reduce the risk of certain complications associated with diabetes over a long period. Glipizid is not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis. The goal of therapy is to support the patient in achieving target blood glucose levels.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Glipizide?

Glipizide's eligibility profile is strictly defined by regulatory documents, allowing its use only in adult patients with Type 2 Diabetes Mellitus.

Contraindicated Populations

Use of Glipizide is absolutely prohibited (contraindicated) for several patient groups, including those with Type 1 Diabetes Mellitus or Diabetic Ketoacidosis (DKA). It is also contraindicated for individuals with a known hypersensitivity to glipizide or to sulfonamide (sulfa) drugs, due to the risk of cross-allergy.

Age and Physiological Restrictions

Population Group Eligibility Status
Pediatric Patients Safety and effectiveness have not been established.
Older Adults Use is permitted, but caution is required due to increased hypoglycemia risk.
Pregnant Women Not generally recommended (contraindicated near term).
Breastfeeding Women Not recommended.

Conditional Use Constraints

Glipizide requires caution and close monitoring in patients with severe hepatic (liver) impairment and severe renal (kidney) impairment. Furthermore, patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency should use the drug with caution due to the risk of hemolytic anemia, as defined in the official prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Glipizide’s interaction profile is categorized by substances that either potentiate or antagonize its effect, alongside medications that alter its plasma concentration. No specific drug-drug combinations are formally classified as contraindicated due to interaction risk in regulatory documents.

Pharmacodynamic Interactions

Co-administration with certain agents may potentiate the hypoglycemic action of Glipizide, which can include classes such as Nonsteroidal Anti-Inflammatory Agents (NSAIDs), MAOIs, Beta-Adrenergic Blocking Agents, and certain highly protein-bound drugs. Conversely, drugs that tend to produce hyperglycemia, such as Thiazides and other Diuretics, Corticosteroids, and Thyroid Products, may lead to a loss of glycemic control.

Exposure-Altering and Timing Interactions

Co-administration with Fluconazole is documented to increase the plasma concentrations of Glipizide. Conversely, Colesevelam significantly reduces the total exposure of Glipizide extended-release tablets. To manage this reduction, the extended-release formulation must be administered at least 4 hours prior to Colesevelam. Furthermore, alcohol consumption is documented to cause either hypoglycemia or hyperglycemia and may prolong the hypoglycemic effect.

Population Considerations

Regulatory information notes that patients with hepatic or renal impairment may experience increased Glipizide blood levels, heightening the risk of severe hypoglycemia. The use of Glipizide (a sulfonylurea) in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency is also associated with the risk of hemolytic anemia.

Mechanism of Action

Glipizide functions as an insulin secretagogue by initiating a molecular cascade within the pancreatic beta-cells that increases insulin release. The drug's action is defined by a primary molecular binding event and the resulting systemic physiological change.

Targeting the ATP-Sensitive Potassium (K ATP) Channel

Glipizide acts directly on the Sulfonylurea Receptor 1 (SUR1), a specific regulatory site on the K ATP channel complex of the beta-cell membrane. This binding causes the immediate closure of the channel, which initiates the entire process of insulin release.

Causal Chain Leading to Insulin Secretion

The K ATP channel closure halts the outflow of potassium ions, leading to membrane depolarization of the beta-cell. This change in electrical charge triggers the opening of voltage-gated Ca^2+ channels, resulting in a rapid surge of intracellular calcium. This increased Ca^2+ concentration acts as the signal that stimulates the beta-cell to release its stored insulin granules (exocytosis).

Systemic Modulation of Glucose Homeostasis

The elevated levels of circulating insulin, a direct result of the pancreatic mechanism, exert a dual systemic effect: enhancing the rate at which peripheral tissues take up glucose and inhibiting the liver's production and release of glucose. These combined physiological adjustments result in a decrease in circulating blood glucose concentration.

Dosage and Administration Information

Administration and Dosing Instructions for Glipizide

Glipizide, a sulfonylurea, is used orally according to specific instructions based on its immediate-release (IR) or extended-release (ER) formulations. These instructions are intended to ensure correct usage.

Administration Details

Administration Component Immediate-Release (IR) Tablets Extended-Release (ER) Tablets
Route of Administration Oral Oral
Timing Relative to Meal Approximately 30 minutes before a meal, typically breakfast. With breakfast or the first main meal of the day.
Preparation Swallow whole. Must be swallowed whole. Do not chew, divide, or crush.

Dosage and Frequency

Starting and maximum daily doses are established as follows:

  • IR Dosing: The initial dose is typically 5 mg once daily. The total daily dose should not exceed 40 mg. Doses above 15 mg are usually divided and taken twice daily (b.i.d.).
  • ER Dosing: The initial dose is typically 5 mg once daily. The maximum recommended daily dose is 20 mg once daily.

Special Population Instructions

For older adults or patients with hepatic (liver) impairment, the starting dose is conservative, often beginning at 2.5 mg for both IR and ER formulations to minimize the risk of adverse effects.

Special Procedural Requirements

Patients taking the bile acid sequestrant colesevelam must take Glipizide at least 4 hours prior to the colesevelam dose. The extended-release formulation should be avoided in patients with severe gastrointestinal narrowing.

Recent Clinical Evidence

Research evidence / Overview of studies for Glipizid

The research evidence for Glipizide primarily comes from randomized controlled trials (RCTs) and systematic reviews, which are a major component of the research used to evaluate a medicine's effects in controlled settings. This research is a primary component of the data package used for regulatory submission, focusing on how the medicine was observed to influence key blood markers in adults with Type 2 Diabetes Mellitus.

Evidence for Use in Type 2 Diabetes Mellitus

Researchers conducted short-term and medium-term Randomized Controlled Trials (RCTs) to evaluate Glipizide's use alongside diet and exercise in adults with Type 2 Diabetes Mellitus. These studies monitored changes in outcomes related to systemic imbalance, specifically focusing on surrogate blood sugar markers like Glycosylated Hemoglobin (HbA1c), Fasting Plasma Glucose (FPG), and Postprandial Glucose (PPG). Researchers examined whether Glipizide influenced these markers over periods often lasting 12 to 16 weeks.

The trials reported measurements where patterns of shift in HbA1c and FPG levels were observed during the study periods. These findings describe patterns observed in the studies in patients with the condition characterized by systemic imbalance associated with high blood sugar. The evidence base regarding the short-term observation of these blood sugar biomarkers is assigned a High level based on established scientific criteria.

Long-Term Research and Durability of Glycemic Control

While initial studies explored short-term changes, researchers also conducted medium-term extension studies, with observation periods extending up to 12 to 15 months, to explore whether patterns of change were maintained on blood glucose biomarkers. These studies monitored whether the observed shifts in biomarkers persisted over longer, defined time intervals.

However, patient-important long-term outcomes are not yet fully characterized regarding critical events beyond blood sugar biomarkers. Research is still emerging, and there is limited information for long-term outcomes that address risks such as heart attack, stroke, or specific diabetes-related complications (e.g., nerve or kidney damage). Evidence for these critical long-term outcomes is not fully developed because many of the core efficacy studies’ follow-up durations were short.

Research in Specific Patient Groups

Glipizide was evaluated in specific patient groups to understand the scope of the research base. Study populations included adults with the condition, encompassing those presenting with both mild and severe hyperglycemia. In addition, research has explored the patterns observed in older patient populations where Glipizide was evaluated. These studies contribute to the broader evidence landscape regarding changes in glucose markers within these specific groups, but results apply only to the populations studied. Data for certain groups remain insufficient, particularly for long-term health outcomes in varied populations.

Research Gaps and Areas of Uncertainty

A primary uncertainty noted by regulatory sources is the lack of conclusive clinical studies that establish evidence of macrovascular risk reduction (the risk of major events like heart attack or stroke) with Glipizide or similar drugs. Limited information for long-term outcomes means that while the medicine has been studied for its effects on blood sugar markers, its eventual influence on preventing these specific diabetes-related complications is not fully established by the existing RCT data. Furthermore, many of the existing trials follow-up durations were short, focusing mainly on short- to medium-term biomarker changes. Comparative evidence is lacking for some of the newer agents, and subgroup findings are uncertain when moving beyond the primary adult T2DM population that research examined. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Glipizide - StatPearls (NCBI Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Glipizide (FAQ)

Q: What is Glipizide used for?

A: Glipizide is an oral prescription medication used, along with diet and exercise, to lower blood sugar in adults with Type 2 diabetes mellitus. It helps your body release its own natural insulin.

Q: How should I take Glipizide?

A: Glipizide is typically taken by mouth, often 30 minutes before a meal to help control the rise in blood sugar after eating. The exact dose and timing depend on the specific formulation (immediate-release or extended-release) and your doctor's instructions. It’s important to take it exactly as prescribed.

Q: What should I do if I miss a dose?

A: If you forget to take a dose, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and continue with your regular schedule. Do not take two doses at once to make up for a missed dose.

Q: What are common side effects of Glipizide?

A: The most common side effect is hypoglycemia (low blood sugar). Signs of low blood sugar can include feeling dizzy, shaky, anxious, confused, or sweaty. Other common side effects may include nausea, diarrhea, constipation, headache, or dizziness.

Q: Can I drink alcohol while taking Glipizide?

A: Limit or avoid drinking alcohol while taking Glipizide. Alcohol can change how Glipizide works and may increase the risk of low blood sugar (hypoglycemia). It can also cause symptoms like flushing, nausea, or rapid heartbeat in some individuals.

Q: Does Glipizide cause weight gain?

A: Yes, weight gain is a possible side effect of Glipizide and other medications in the sulfonylurea class. Discuss any concerns about weight changes with your healthcare provider, as diet and exercise are key parts of diabetes management.

How should Glipizid be stored and disposed of?

Glipizide Storage and Disposal Instructions

Glipizide tablets must be stored at controlled room temperature, which is defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The medication must be protected from moisture and should be kept in a tightly closed container to maintain its stability. Do not store the product in a damp place, such as a bathroom.

All Glipizide tablets must be stored out of the reach of children.

Disposal Instructions

Disposal of any unused or expired Glipizide must comply with local requirements. It should not be flushed down the toilet or poured into a drain unless instructed to do so by an authorized governmental disposal program. The use of a drug take-back site or program is recommended for proper disposal of unused medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Glipizid found in:

A-Z Index: